Semax is a synthetic ACTH‑derived peptide that users take for cognitive enhancement and, to a lesser extent, for focus and attention. Community reports describe daily dosing between 200 µg and 600 µg, most often administered orally; one clinician source recommends a 20‑days‑on/10‑days‑off cycle, while other guidance notes that continuous use beyond several weeks lacks study and may provoke nasal irritation. The main drawback is that Semax has no FDA‑approved indication, so all human use is off‑label and compounded, and injection‑site or nasal irritation appears repeatedly in anecdotal reports.

Research Evidence
Evidence shape
The only clinical evidence for Semax is animal‑only research, confined to preclinical mechanistic studies. No registered or completed human trials exist, and there are no blinded or multi‑sponsor data sets to speak of. Consequently, any claims about efficacy in people lack support from human research.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Semax is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
Clinician protocols dose 200 µg–600 µg daily oral (3 sources).
No structured protocol details captured for this tier yet.
Across 8 Reddit reports, 6 focus on cognitive enhancement (66.7 % positive, 16.7 % mixed, 16.7 % negative) and 2 on focus/attention (50 % positive, 50 % negative). No concrete dose information was shared in these posts.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for Semax, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.